Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3077340 | 0.76 | PGD (0.31) | — | |
| SCHEMBL3080212 | 0.76 | PGD (0.31) | — | |
| SCHEMBL3084980 | 0.75 | SLC1A3 (0.37) | CYP2C19MAOBKMT2A | |
| SCHEMBL3087110 | 0.72 | — | — | |
| SCHEMBL3070738 | 0.68 | GLI1 (0.43) | CA2ESR1ESR2TRPV1KDM4E | |
| SCHEMBL8758151 | 0.66 | MET (0.56) | METCA12CA1CA4CA6 | |
| SCHEMBL274512 | 0.65 | ESR1 (0.48) | CA2ESR1ESR2NPC1MAPT | |
| SCHEMBL3081598 | 0.64 | DDAH1 (0.34) | — | |
| SCHEMBL9725762 | 0.64 | ESR1 (0.52) | CA2ESR1ESR2NPC1MAPT | |
| SCHEMBL1586370 | 0.62 | SLC7A5 (0.49) | CA2ESR1ESR2TRPV1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790926-B2 | Alpha, omega-difunctional aldaramides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7351862-B2 | Alpha, omega-difunctional aldaramides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1853554-A2 | ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060258886-A1 | Alpha, omega-difuctional aldaramides | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| WO-2006091902-A2 | ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258886-A1 | Alpha, omega-difuctional aldaramides | FADS2, FASN, DEGS1 | MET 2958/4885CA12 3316/4885CA1 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.